ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Association of Blood Levels of Forever Plastics with Lung Cancer Mortality among Ever Smokers in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cohort Study.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeRecent evidence suggests a significant association between microplastic (MP), forever chemicals, and plasticizers and various diseases, including cancer. In this study, we evaluated circulating levels of plastic-associated chemicals in relation to lung cancer incidence and mortality among smokers in the Prostate, Lung, Colorectal, and Ovarian (PLCO) study. EXPERIMENTAL
designUsing mass spectrometry, we screened for 29 known MP, forever plastics [per- and polyfluoroalkyl substances (PFAS)], and plasticizer chemicals in 245 sera collected preceding a lung cancer diagnosis and 1,200 noncase sera from participants in the PLCO study who had a history of smoking. Five PFAS and three plasticizers were detected and quantified in sera. A PFAP model, consisting of perfluorooctane sulfonate (PFOS) + perfluorohexanesulfonic acid (PFHA) + mono-iso-nonyl phthalate, was developed for predicting lung cancer mortality and risk strata based on quantiles established.
resultsHigher circulating levels of PFOS, PFHA, and mono-iso-nonyl phthalate were associated with increased risk of lung cancer death (P < 0.05) but not incidence. Compared with the lowest quantile (reference), individuals with PFAP scores in the highest quantile were at markedly higher risk of death from lung cancer (P < 0.0001), with respective cause-specific and subdistributional HR of 1.86 [95% confidence interval (CI), 1.18-2.93] and 1.82 (95% CI, 1.15-2.88). Substratified analyses confirmed that the PFAP model remained an independent predictor of lung cancer-specific mortality (P < 0.05) across strata defined by age, sex, smoking history, histologic subtype, and stage at diagnosis.
conclusionsIn the PLCO cohort, elevated levels of PFOS, PFHA, and mono-iso-nonyl phthalate were associated with increased lung cancer mortality among ever smokers across disease subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.